We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
T33.4
T3 (Liothyronine) Research
Mostly mechanism / observationalLimited safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most T3 (Liothyronine) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1984–2025 with a typical study size of 12 participants.
Based on 7 studies · 3 meta-analyses · 1 RCT · 2,025 total participants
Confidence
High
By outcome
Thyroid & hypothyroidism (approved use)
Mostly mechanism / observational4 studies
Weight & fat loss (off-label)
Mostly mechanism / observational3 studies
Cardiac & arrhythmia
Mostly mechanism / observational3 studies
Lean mass & muscle loss
Too few graded studies2 studies
Bone health
Too few graded studies1 study
Safety profile
Too few graded studies1 study
Active research area
4 studies in the last 5 years · Latest meta-analysis: 2025
198420042025
1Meta-Analysis2025
LT3-related AEs were only reported with unregulated LT3 use or pharmacy compounding errors ... regulated LT3 use is not associated with the risk of death or serious AEs.
Bahl S, Taylor PN, Premawardhana LD, Stedman M, Heald A, Dayan CM, Okosieme OE · The Journal of clinical endocrinology and metabolism (2025)
Most recent, largest safety synthesis: a multisource systematic review and meta-analysis (52 studies incl. 21 RCTs, 4 cohorts, FAERS and Yellow Card pharmacovigilance)
In a 630,254-person cohort meta-analysis, regulated LT3 use showed no increased atrial fibrillation, heart failure, or stroke risk versus LT4 alone (and lower mortality) — the safety signal is REGULATED-use reassurance, not endorsement of physique misuse
Crucially, adverse events were reported only with UNREGULATED liothyronine use or pharmacy compounding errors — the exact scenario of off-label grey-market fat-loss use
Combined therapy and DTE lead to higher T3 and lower T4 levels, compared to T4 monotherapy in hypothyroidism. However, no significant effects on heart rate, lipid profile, or quality of life were noted.
Nassar M, Hassan A, Ramadan S, Desouki MT, Hassan MA, Chaudhuri A · BMC endocrine disorders (2024)
Systematic review and meta-analysis of 16 RCTs of combined T4+T3 (or desiccated thyroid) versus levothyroxine monotherapy in hypothyroidism — the approved-use context
Combination therapy raised total T3 and modestly improved one subjective measure (GHQ-28) but showed no significant advantage in heart rate, lipid profile, or other quality-of-life scores
Top-tier synthesis for T3's only evidence-based indication: it does not establish a clear objective benefit of adding T3 over T4 alone
Among people 60 years of age or older, a low serum thyrotropin concentration is associated with a threefold higher risk that atrial fibrillation will develop in the subsequent decade.
Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB · The New England journal of medicine (1994)
Cardiac counter-evidence: a 10-year prospective Framingham cohort of 2007 adults aged 60+ without baseline atrial fibrillation
A low serum thyrotropin (TSH ≤ 0.1 mU/L) — the biochemical hallmark of supraphysiologic thyroid-hormone exposure — carried a 3.1-fold adjusted relative risk of incident atrial fibrillation
Directly relevant to off-label T3 use, which suppresses TSH: suppressing the thyroid axis is itself a measurable arrhythmia risk factor
Stringent TSH suppression had deleterious effects on the BMD of the lumbar spine after thyroidectomy in postmenopausal women.
Kwak D, Ha J, Won Y, Kwon Y, Park S · BMJ open (2021)
Bone counter-evidence: systematic review and meta-analysis of 16 case-control studies (426 patients, 701 controls) of postmenopausal women
Stringent TSH suppression (TSH < 0.10 mIU/L) significantly lowered lumbar-spine bone mineral density (SMD -0.55), with total thyroidectomy also harming femoral-neck BMD
Generalizes the bone risk of the suppressed-TSH state that supraphysiologic T3 produces — relevant to long-term off-label use, especially in women
The pharmacokinetics of liothyronine causes concerns for cardiovascular toxicity ... Following the administration of liothyronine, serum T3 reached a Cmax of 421 ng/dL ... No differences between study arms were observed in heart rate, blood pressure, hemodynamics parameters, energy expenditure.
Chen S, Wohlford GF, Vecchie' A, Carbone S, Yavuz S, Van Tassell B, Abbate A, Celi FS · Frontiers in endocrinology (2022)
Double-blind, placebo-controlled, three-arm crossover RCT in 12 healthy volunteers given oral liothyronine, equimolar levothyroxine, or placebo
Establishes liothyronine's pharmacokinetics (high peak T3) and that it acts on energy metabolism and the cardiovascular system — the mechanism behind the off-label metabolic use
A single high dose produced no acute change in resting energy expenditure or cardiac parameters in healthy young subjects — the cardiovascular concern is with sustained/supraphysiologic exposure, not one acute dose
Most notable was the strong negative correlation between the size of the decrease in serum triiodothyronine ... and the magnitude of the concurrent cumulative N deficit ... one's ability to decrease circulating serum triiodothyronine levels may be critical to achievement of an adaptational decrease in body protein loss.
Yang MU, van Itallie TB · The American journal of clinical nutrition (1984)
Six morbidly obese subjects studied for 64 days on a 600–800 kcal/day metabolic-ward diet, with detailed body-composition and nitrogen-balance measurement
The body's adaptive FALL in serum T3 during dieting was strongly associated with LESS body-protein (lean-mass) loss — the natural drop in T3 protects muscle
Implies that propping T3 up (or raising it) during a diet works against muscle preservation — mechanistic counter-evidence to off-label cutting use
T3 increased the rate of weight loss, with a significant increase in urinary nitrogen excretion ... the extra weight loss produced by T3 was at the expense of lean body mass and not of fat.
Wolman SI, Sheppard H, Fern M, Waterlow JC · International journal of obesity (1985)
Mandatory counter-evidence for the fat-loss claim: obese patients on a restricted-energy diet given T3 (20 mcg three times daily) for ~2 weeks lost more weight — but the extra loss was lean body mass, not fat
T3 significantly increased urinary nitrogen excretion (a marker of muscle/protein breakdown) with only small, non-significant rises in basal metabolic rate and protein turnover
Directly contradicts the physique rationale: supraphysiologic T3 added to a diet accelerates muscle loss, the opposite of a 'cutting' goal